Guest lecture by Simon Salzman from Boehringer Ingelheim at EBS
After working in corporate finance and investment banking at Accuracy and Lincoln International Simon “switched sides” and now leads M&A deals at Boehringer Ingelheim.
In his talk, Simon shared valuable insights into current M&A dynamics in the pharma industry:
- While the COVID-19 crisis is often compared to the credit crunch in 2007/2008, markets have quickly recovered and a surge in strategic deal activity can be observed.
- The existing liquidity in the market continues to finance rising biotech firms, which outperform classical pharma companies’ performance.
- Under these circumstances, pharma incumbents need to navigate corporate development modes diligently: Early ties to aspiring biotech firms can lead to valuable advantages in the bidding process.
- The acquisition process does not stop after the deal transaction: To leverage the biotech firms’ unique intellectual property, post-merger integration strategies already need to be crafted while assessing the target company.